Screener
Generate Biomedicines, Inc. GENB Income Statement
| Q2 '26 | Q1 '26 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|
| $6.31M-37.7% | $7.22M-18.1% | $10.13M— | $8.82M— | ||
| $64.33M+7.7% | $57.81M+23.5% | $59.74M— | $46.83M— | ||
| $13.6M+29.0% | $13.52M+33.3% | $10.55M— | $10.15M— | ||
| $77.93M+10.9% | $71.34M+25.2% | $70.28M— | $56.97M— | ||
| -$71.61M-19.1% | -$64.11M-33.1% | -$60.15M— | -$48.15M— | ||
| -1,134.2%-540pp | -887.5%-341pp | -593.8%— | -546.1%— | ||
| $155K-49.5% | $182K-50.5% | $307K— | $368K— | ||
| $4.41M+27.8% | $2.43M-37.7% | $3.45M— | $3.9M— | ||
| -$67.2M-18.5% | -$61.69M-39.4% | -$56.7M— | -$44.26M— | ||
| $53K+20.5% | $28K-50.0% | $44K— | $56K— | ||
| -$67.26M-28.3% | -$61.45M-47.4% | -$52.43M— | -$41.69M— | ||
| -1,065.2%-548pp | -850.6%-378pp | -517.6%— | -472.7%— | ||
| -$0.52+73.2% | -$1.07+34.0% | -$1.94— | -$1.62— | ||
| -$68.41M-20.3% | -$60.84M-36.0% | -$56.85M— | -$44.74M— | ||
| -1,083.5%-522pp | -842.2%-335pp | -561.2%— | -507.4%— | ||
| -$71.61M-19.1% | -$64.11M-33.1% | -$60.15M— | -$48.15M— |
FAQ
- What is Generate Biomedicines, Inc.'s revenue?
- Generate Biomedicines, Inc. (GENB) generated $32.5M in revenue over the trailing twelve months.
- Is Generate Biomedicines, Inc. profitable?
- Generate Biomedicines, Inc. is not currently profitable: it reported a net loss of $222.8M over the trailing twelve months, a -685.9% net margin.
- What is Generate Biomedicines, Inc.'s earnings per share?
- Generate Biomedicines, Inc.'s diluted EPS over the trailing twelve months is $-5.15.
- Where does Generate Biomedicines, Inc.'s income statement data come from?
- Every line is extracted from Generate Biomedicines, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
